BRPI1010540A2 - "anticorpos especéficos para dkk-1 e seus usos" - Google Patents
"anticorpos especéficos para dkk-1 e seus usos"Info
- Publication number
- BRPI1010540A2 BRPI1010540A2 BRPI1010540A BRPI1010540A BRPI1010540A2 BR PI1010540 A2 BRPI1010540 A2 BR PI1010540A2 BR PI1010540 A BRPI1010540 A BR PI1010540A BR PI1010540 A BRPI1010540 A BR PI1010540A BR PI1010540 A2 BRPI1010540 A2 BR PI1010540A2
- Authority
- BR
- Brazil
- Prior art keywords
- dkk
- antibodies specific
- antibodies
- specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17765009P | 2009-05-12 | 2009-05-12 | |
| US24463809P | 2009-09-22 | 2009-09-22 | |
| PCT/IB2010/052056 WO2010131185A1 (en) | 2009-05-12 | 2010-05-10 | Blocking anti-dkk-1 antibodies and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1010540A2 true BRPI1010540A2 (pt) | 2016-03-15 |
Family
ID=42315893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1010540A BRPI1010540A2 (pt) | 2009-05-12 | 2010-05-10 | "anticorpos especéficos para dkk-1 e seus usos" |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8338576B2 (pt) |
| EP (1) | EP2430048A1 (pt) |
| JP (1) | JP2012526542A (pt) |
| KR (1) | KR101471239B1 (pt) |
| CN (1) | CN102666584A (pt) |
| AR (1) | AR076668A1 (pt) |
| AU (1) | AU2010246981B2 (pt) |
| BR (1) | BRPI1010540A2 (pt) |
| CA (1) | CA2761696A1 (pt) |
| CO (1) | CO6460768A2 (pt) |
| IL (1) | IL216304A0 (pt) |
| MX (1) | MX2011012039A (pt) |
| NZ (1) | NZ596274A (pt) |
| PE (1) | PE20120475A1 (pt) |
| RU (1) | RU2548817C2 (pt) |
| SA (1) | SA110310369B1 (pt) |
| SG (1) | SG175881A1 (pt) |
| TW (1) | TWI411444B (pt) |
| WO (1) | WO2010131185A1 (pt) |
| ZA (1) | ZA201108310B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2705879A1 (en) * | 2007-11-21 | 2009-06-04 | Amgen Inc. | Wise binding agents and epitopes |
| MX354481B (es) * | 2010-10-27 | 2018-03-07 | Amgen Inc | Anticuerpos dkk1 y métodos de uso. |
| EP2668210B1 (en) | 2011-01-26 | 2020-06-17 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| WO2012154983A2 (en) | 2011-05-10 | 2012-11-15 | Biocare Medical, Llc | Systems and methods for anti-pax8 antibodies |
| US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
| NZ630363A (en) * | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
| DK2900265T3 (en) | 2012-09-27 | 2018-08-20 | Biocare Medical Llc | Anti-Uroplakin II Antibodies, Systems and Methods |
| US10429390B2 (en) | 2012-12-18 | 2019-10-01 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
| ES2720483T3 (es) | 2013-02-28 | 2019-07-22 | Biocare Medical Llc | Sistemas y procedimientos de anticuerpos anti p40 |
| GB201312638D0 (en) * | 2013-07-15 | 2013-08-28 | King S College London | Biomarkers |
| EP3052522B1 (en) | 2013-10-03 | 2019-12-11 | Biocare Medical, LLC | Anti-sox10 antibody systems and methods |
| AU2016263030A1 (en) | 2015-05-18 | 2017-10-12 | Eli Lilly And Company | Anti-Dkk-1-anti-RANKL bispecific antibody compounds |
| CN111556895A (zh) * | 2017-11-14 | 2020-08-18 | 中外制药株式会社 | 抗-c1s抗体及使用方法 |
| EP3787645A4 (en) * | 2018-05-02 | 2022-06-01 | Ortheus, Inc. | SYSTEMS AND METHODS FOR LOCAL MODULATION OF THE WNT SIGNALING PATHWAY |
| CN112180094A (zh) * | 2019-07-04 | 2021-01-05 | 上海东慈生物科技有限公司 | Dkk1抑制剂在预防和/或治疗肿瘤恶病质与糖尿病伴随疾病中的应用 |
| KR102192471B1 (ko) * | 2019-10-18 | 2020-12-17 | 주식회사 인코스팜 | 탈모 완화 및 모발 성장을 촉진시키는 펩타이드 및 이를 포함하는 화장료 조성물 |
| KR102494042B1 (ko) * | 2020-11-20 | 2023-02-07 | 주식회사 하울바이오 | 인간모유두세포의 성장을 촉진하는 항-dkk-1 항체 및 이의 용도 |
| CN112592402B (zh) * | 2020-12-02 | 2022-04-26 | 杭州奕安济世生物药业有限公司 | 抗dkk2抗体、包含该抗dkk2抗体的组合物及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7057017B2 (en) | 1997-04-16 | 2006-06-06 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| US6391311B1 (en) | 1998-03-17 | 2002-05-21 | Genentech, Inc. | Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1 |
| DE19747418C1 (de) | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US7446181B2 (en) | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| EP1490386B1 (en) | 1998-03-10 | 2008-08-13 | Genentech, Inc. | Novel polypeptide and nucleic acids encoding the same |
| US6962797B2 (en) | 1998-04-15 | 2005-11-08 | Genentech, Inc. | Nucleic acids encoding PRO615 |
| US6344541B1 (en) | 1998-09-25 | 2002-02-05 | Amgen Inc. | DKR polypeptides |
| US20030203446A1 (en) | 1998-10-07 | 2003-10-30 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US6673549B1 (en) | 2000-10-12 | 2004-01-06 | Incyte Corporation | Genes expressed in C3A liver cell cultures treated with steroids |
| CA2438245A1 (en) * | 2001-02-16 | 2002-08-29 | Genentech, Inc. | Treatment involving dkk-1 or antagonists thereof |
| JP2005512508A (ja) * | 2001-05-17 | 2005-05-12 | ゲノム セラピューティックス コーポレーション | Ｄｋｋ媒介性相互作用を変調する試薬および方法 |
| US20040038860A1 (en) | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| US7371736B2 (en) | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
| EP1461448A2 (en) | 2001-11-07 | 2004-09-29 | The Board Of Trustees Of The University Of Arkansas | Diagnosis prognosis and identification of potential therapeutic targets of multiple myeloma based on gene expression profiling |
| US7894992B2 (en) | 2001-11-07 | 2011-02-22 | Board Of Trustees Of The University Of Arkansas | Diagnosis and classification of multiple myeloma |
| US7308364B2 (en) | 2001-11-07 | 2007-12-11 | The University Of Arkansas For Medical Sciences | Diagnosis of multiple myeloma on gene expression profiling |
| US8124087B2 (en) | 2002-12-05 | 2012-02-28 | Board Of Trustees Of The University Of Arkansas | Methods of controlling bone loss by inhibiting DKK1 |
| MXPA05006033A (es) | 2002-12-05 | 2006-03-08 | Univ Arkansas | Determinantes moleculares de enfermedad osea por mieloma, y usos de los mismos. |
| US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US7811750B2 (en) | 2002-12-05 | 2010-10-12 | Board Of Trustees Of The University Of Arkansas | Molecular determinants of myeloma bone disease and use thereof |
| US20050084494A1 (en) | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
| US8637506B2 (en) | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US8343922B2 (en) | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| EP1786837B1 (en) | 2004-08-04 | 2013-05-01 | Amgen Inc., | Antibodies to dkk-1 |
| AR060017A1 (es) * | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| WO2008070112A1 (en) | 2006-12-06 | 2008-06-12 | The Board Of Trustees Of The University Of Arkansas | Overexpression of wnt ligands and treatment of lytic bone diseases |
| JP2010517570A (ja) * | 2007-02-08 | 2010-05-27 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｄｋｋ−１に特異的な抗体 |
| AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
-
2010
- 2010-05-10 CN CN2010800316466A patent/CN102666584A/zh active Pending
- 2010-05-10 NZ NZ596274A patent/NZ596274A/xx not_active IP Right Cessation
- 2010-05-10 CA CA2761696A patent/CA2761696A1/en not_active Abandoned
- 2010-05-10 JP JP2012510415A patent/JP2012526542A/ja not_active Ceased
- 2010-05-10 WO PCT/IB2010/052056 patent/WO2010131185A1/en active Application Filing
- 2010-05-10 SG SG2011081080A patent/SG175881A1/en unknown
- 2010-05-10 RU RU2011145435/10A patent/RU2548817C2/ru not_active IP Right Cessation
- 2010-05-10 BR BRPI1010540A patent/BRPI1010540A2/pt not_active IP Right Cessation
- 2010-05-10 MX MX2011012039A patent/MX2011012039A/es active IP Right Grant
- 2010-05-10 EP EP10721057A patent/EP2430048A1/en not_active Ceased
- 2010-05-10 SA SA110310369A patent/SA110310369B1/ar unknown
- 2010-05-10 AU AU2010246981A patent/AU2010246981B2/en not_active Ceased
- 2010-05-10 KR KR1020117029598A patent/KR101471239B1/ko not_active IP Right Cessation
- 2010-05-10 AR ARP100101589A patent/AR076668A1/es unknown
- 2010-05-10 PE PE2011001952A patent/PE20120475A1/es not_active Application Discontinuation
- 2010-05-11 US US12/777,806 patent/US8338576B2/en not_active Expired - Fee Related
- 2010-05-11 TW TW099115010A patent/TWI411444B/zh not_active IP Right Cessation
-
2011
- 2011-11-10 IL IL216304A patent/IL216304A0/en unknown
- 2011-11-11 ZA ZA2011/08310A patent/ZA201108310B/en unknown
- 2011-11-15 CO CO11155162A patent/CO6460768A2/es active IP Right Grant
-
2012
- 2012-11-19 US US13/680,569 patent/US8586721B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010246981B2 (en) | 2013-12-19 |
| US8338576B2 (en) | 2012-12-25 |
| US20130071921A1 (en) | 2013-03-21 |
| PE20120475A1 (es) | 2012-05-05 |
| SG175881A1 (en) | 2011-12-29 |
| JP2012526542A (ja) | 2012-11-01 |
| TW201043247A (en) | 2010-12-16 |
| EP2430048A1 (en) | 2012-03-21 |
| CO6460768A2 (es) | 2012-06-15 |
| ZA201108310B (en) | 2013-04-24 |
| SA110310369B1 (ar) | 2014-09-02 |
| NZ596274A (en) | 2013-11-29 |
| KR101471239B1 (ko) | 2014-12-09 |
| CA2761696A1 (en) | 2010-11-18 |
| US8586721B2 (en) | 2013-11-19 |
| WO2010131185A1 (en) | 2010-11-18 |
| KR20120007078A (ko) | 2012-01-19 |
| CN102666584A (zh) | 2012-09-12 |
| AR076668A1 (es) | 2011-06-29 |
| RU2011145435A (ru) | 2013-06-20 |
| RU2548817C2 (ru) | 2015-04-20 |
| US20100291076A1 (en) | 2010-11-18 |
| IL216304A0 (en) | 2012-01-31 |
| TWI411444B (zh) | 2013-10-11 |
| AU2010246981A1 (en) | 2011-12-08 |
| MX2011012039A (es) | 2011-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1010540A2 (pt) | "anticorpos especéficos para dkk-1 e seus usos" | |
| BRPI1012321A2 (pt) | anticorpos anti-vegf e seus usos | |
| BRPI1009455A2 (pt) | anticorpos anti-c40 e usos dos mesmos | |
| BR112012000882A2 (pt) | Preparação cosmética capilar e método para aplicação. | |
| BRPI0913707A2 (pt) | "artigo e métodos para preparação do artigo" | |
| BRPI0910746A2 (pt) | reticuladores e seus usos | |
| BR112012025697A2 (pt) | "dispositivo e método para conjunto estrutural" | |
| BR112012031446A2 (pt) | componentes e métodos para implantes | |
| BRPI1011384A2 (pt) | pro-proteinas e seus metodos de uso | |
| BRPI0819909A2 (pt) | anticorpos antimesotelina e usos dos mesmos | |
| BRPI0906498A2 (pt) | Anticorpo ron e seus usos | |
| BRPI0906387A2 (pt) | Anticorpos alfa 5 - beta 1 e seus usos | |
| BRPI1010075A2 (pt) | ''núcleo absorvente e artigo absorvente'' | |
| BRPI0913640A2 (pt) | substâncias policrômicas e seus usos | |
| BR112012004526A2 (pt) | "estrutura de suporte e contenção para pessoas" | |
| BR112012001797A2 (pt) | composto bicíclico e uso do mesmo para propósitos médicos | |
| BR112013023743A2 (pt) | anticorpo de fator de tecidos humanos e usos do mesmo | |
| BRPI1014262A2 (pt) | anticorpos específicos para caderina-17 | |
| BR112012004647A2 (pt) | artigo absorvente e aparelho de fabricação para artigo absorvente | |
| BRPI0921862A2 (pt) | inibidores de raf e seus usos | |
| BRPI0907247A2 (pt) | Métodos para preparar biopterina e para preparar tetraidrobiopterina | |
| BRPI0912687A2 (pt) | uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia | |
| BR112013014540A2 (pt) | artigo absorvente e método para preparar o mesmo | |
| BR112013008898A2 (pt) | benzamidas substituídas e seus usos | |
| ES1071388Y (es) | Estructura para la formacion de instalaciones multi-aventura |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |